Exelixis Announces August 5 Webcast of Second Quarter 2010 Financial Results Conference Call

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq:EXEL) will release its second quarter 2010 financial results on Thursday, August 5, 2010 after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. ET/ 2:00 p.m. PT, in which Exelixis management will discuss the financial results, financial outlook, and provide a general business update. The webcast may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

An audio replay of the webcast will be available until 11:59 p.m. ET/ 8:59 p.m. PT on September 5, 2010. Access numbers for the replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international), and the passcode is 55929379.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer and potentially other serious diseases. Currently, Exelixis’ broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo. For more information, please visit the company’s web site at http://www.exelixis.com.

Exelixis and the Exelixis logo are registered U.S. trademarks.



CONTACT:

Exelixis, Inc.
Investor Contacts:
Charles Butler, 650-837-7277
Vice President
Investor Relations
and Corporate Communications
[email protected]
DeDe Sheel, 650-837-8231
Associate Director,
Investor Relations
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.